Back to discover
Drug

Lutetium-177

In clinical development
Emerging researchEarly-to-mid developmentRising momentum
Also known as 177Lu, Lu 177, Lu-177, Lutetium Lu 177+1 more

177Lu, Lu 177, Lu-177, Lutetium Lu 177, Lutetium Lu-177.

RxNorm1997335UNIIBRH40Y9V1Q
3
Research papers
2
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Phase Ib Study of Cabozantinib in Combination With Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Progressive, Previously Treated Somatostatin Receptor 2 (SSTR2) Positive Neuroendocrine Tumors (NETs)

Clinical trial2026-04-13Results expected Q4 2027 · ClinicalTrials.gov

Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function

Clinical trial2026-04-02Results expected Q3 2026 · ClinicalTrials.gov

177Lu-LNC1004 Radioligand Therapy in Patients with End-stage Metastatic Cancers: A Single-Center, Single-Arm, Phase II Study.

Research2025-04-01Clinical cancer research : an official journal of the American Association for Cancer Research

Quantitative <sup>68</sup>Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following <sup>177</sup>Lu-PSMA-617 (VISION Trial).

Research2024-08-01Radiology

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Research2021-06-23The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Lutetium-177
Aliases & brands
177LuLu 177Lu-177Lutetium Lu 177Lutetium Lu-177
RxNorm CUI
1997335
UNII
BRH40Y9V1Q

Clinical trials

2 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
2
registered trials across all phases
2
Active studies
1
Recruiting
1
Late-stage (III+)
PHASE DISTRIBUTIONn = 2
Phase 11Phase N / A1

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20212025
Major research themes8
Lutetium2Radiopharmaceuticals2Dipeptides1Gallium Isotopes1Gallium Radioisotopes1Heterocyclic Compounds, 1-Ring1Membrane Proteins1Neoplasms1
Journals, researchers & institutions
Top journals
  • Clinical cancer research : an official journal of the American Association for Cancer Research1
  • Radiology1
  • The New England journal of medicine1
Leading researchers
  • de Bono J2
  • Fizazi K2
  • Herrmann K2
  • Morris MJ2
  • Rahbar K2
  • Sartor O2
  • Tagawa ST2
  • Adra N1
Leading institutions
free-text, unnormalised
  • Clinical Imaging Research Centre1
  • College of Design and Engineering1
  • Department of Nuclear Medicine and Minnan PET Center1
  • From the School of Medicine1
  • From the University of Arizona1
  • Institute of Molecular and Cell Biology1

Related diseases

1 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Related drugs

3 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Lutetium

Studied across 3 of the same disease areas as Lutetium-177 in the shared literature.

3 shared diseases3 shared papers
Edetic Acid

Studied across the same disease area as Lutetium-177 in the shared literature.

1 shared disease1 shared paper
lutetium Lu 177 vipivotide tetraxetan

Studied across the same disease area as Lutetium-177 in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials